Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 12/20 | 0.70 |
| ▸ | SCD5 | Q86SK9 | 10/20 | 0.70 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.64 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.64 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.64 |
| ▸ | CLK2 | P49760 | 2/20 | 0.64 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.64 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.64 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673041 | 0.97 | SCD (0.66) | SCDSCD5ROCK2CLK4STK17A | |
| SCHEMBL3670699 | 0.87 | SCD5 (0.66) | SCDSCD5ROCK2CLK4STK17A | |
| SCHEMBL3668953 | 0.86 | ROCK2 (0.58) | SCDSCD5ROCK2CLK4STK17A | |
| SCHEMBL3673647 | 0.83 | ROCK2 (0.72) | SCDSCD5ROCK2CLK4STK17A | |
| SCHEMBL21535917 | 0.83 | SCD (1.00) | SCDSCD5 | |
| SCHEMBL21536326 | 0.83 | SCD (1.00) | SCDSCD5 | |
| SCHEMBL21535920 | 0.83 | SCD (1.00) | SCDSCD5 | |
| SCHEMBL21535925 | 0.79 | SCD (1.00) | SCDSCD5 | |
| SCHEMBL21536529 | 0.79 | SCD5 (1.00) | SCDSCD5 | |
| SCHEMBL21536546 | 0.79 | SCD (1.00) | SCDSCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | claimed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | SCD 3947/4885SCD5 3059/4885ROCK2 48/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | SCD 3947/4885SCD5 3059/4885ROCK2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.